After digging into almost a dozen whistleblower complaints alleging pharma companies ran kickback schemes with nurse educators as the “payment”—so-called white-coat marketing—the government is backing out. More: Feds abandon 11 'white-coat' kickback probes, questioning whistleblower motives instead Source: fierce
read moreA Recipharm plant in the U.K. has been on the edge financially for some time, having been unprofitable for three years. Now, the Swedish-based CDMO says the cost of fixing issues raised by U.K. authorities may be the breaking point.
read moreLilly provided a forecast for next year that beat analysts’ expectations—welcome news as its blockbuster Cialis faces generic rivals. More: Lilly lays out sunny 2019 forecast driven by growth of new diabetes, psoriasis and cancer drugs Source: fierce
read moreWhat’s bad for Johnson & Johnson shares is good for the trial lawyer leading the charge in the talc liability litigation—or so the lawyer says, as J&J scrambles to contain the damage from a bombshell Reuters report Friday. More: Talc
read moreIn this issue, FiercePharmaMarketing looks back—and forward—to the focal points and features of 2018 that will keep trending in 2019. More: Politics and tech cap 2018 in pharma marketing, and they'll trend in 2019, too Source: fierce
read moreBruntwood SciTech has announced a £10 million investment into the life sciences sector, in the form of 50,000 square feet of office space and laboratory facilities in Alderley Park, Cheshire. More: Bruntwood to make £10M life science investment Source: News
read more© 1994 - 2026 B.M. Pharmaceuticals